| Document Date: 2014-10-01 21:56:22
Open Document File Size: 145,77 KBShare Result on Facebook
Company PBAC / UCB Australia Pty Ltd / Lennox / / Country Australia / / Currency USD / JPY / / Event FDA Phase / Product Issues / Product Recall / / Holiday Commonwealth Day / / IndustryTerm prescriptions processing / treatment algorithm / / MedicalCondition partial seizures / seizures / specialist epilepsy / intractable epilepsy / treatmentresistant partial-onset seizures / refractory partial seizures / drug resistant epilepsy / partial epilepsy / refractory partial epilepsy / partialonset seizures / secondarily generalised seizures / partial onset seizures / primary generalised tonicclonic epileptic seizures / partial-onset seizures / patient’s seizures / recurrent / unprovoked seizures / uncontrolled seizures / partial epileptic seizures / medically intractable partial Study Group epilepsies / migraine / seizure / Proposed Therapy Epilepsy / epilepsy / dizziness / intractable partial epileptic seizures / / MedicalTreatment surgery / adjunctive therapy / drug therapy / / Organization Advisory Board / Streamlined Authority Required / Listing Requested and PBAC’s View Authority / / Position neurologist / nurse / Trial ID/ First author / / Product topiramate / carbamazepine / zonisamide / Lacosamide / phenytoin / lamotrigine / gabapentin / Public Summary Document / oxcarbazepine / PBS prescriptions / SP667 / / Technology author Protocol / placebo SP667 Protocol / treatment algorithm / /
SocialTag |
PUBLIC SUMMARY DOCUMENT Product: Lacosamide, tablets, 50 mg, 100 mg, 150 mg and 200 mg, Vimpat® Sponsor: UCB Australia Pty Ltd Date of PBAC Consideration: NovemberPurpose of Application